Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease

Lancet

Volumn 350, Issue 9085, 1997, Pages 1136-1139

  Bandmann, O ^a   Vaughan, J ^a   Holmans, P ^b   Marsden, C D ^a   Wood, N W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; DNA; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ACETYLATOR PHENOTYPE; AGED; ARTICLE; BLOOD SAMPLING; BRAIN; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING;

EID: 0030692086     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03495-8     Document Type: Article

References (36)

1. Rijk M, Tzourio C, Breteler M, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 1997; 62: 10-15.
2. Gibb W. The pathology of parkinsonian disorders. In: Quinn N, Jenner P, eds. Disorders of movement. London: Academic Press, 1989: 33-57.
3. Polymeropoulos M, Higgins J, Golbe L, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-23. Science 1996; 274: 1197-99.
4. Wood NW. Genes and parkinsonism. J Neurol Neurosurg Psychiatry 1997; 62: 305-09.
5. Seidler A, Hellenbrand W, Robra B-P, et al. Possible environmental, occupational and other ecological factors for Parkinson's disease: a case control study in Germany. Neurology 1996; 46: 1275-84.
6. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-98.
7. Schapira A. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994; 9: 125-38.
8. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45: 1041-51.
9. Lin H, Han C-Y, Lin B, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-34.
10. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017-18.
11. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-77.
12. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P450IID6 mutant gene associated wtih Parkinson's disease. J Biochem 1993; 114: 263-66.
13. Diederich N, Hilger C, Goetz C, Vieregge P, Metz H. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40: 463-65.
14. Montoliu C, Sancho-Tello M, Azorin M, et al. Ethanol induces cytochrome P4502E1 and induces oxidative stress in astrocytes. J Neurochem 1995; 65: 2561-70.
15. Dexter D, Carter C, Agid F, et al. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 1986; ii: 639-40.
16. Sian J, Dexter D, Lees A, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 1994; 36: 348-55.
17. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991; 110: 559-65.
18. Traver R, Horikoshi T, Danenberg K, et al. NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52: 797-802.
19. Sies H, Ketterer B. Glutathione conjugation: mechanisms and biological significance. New York: Academic Press, 1988.
20. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study. J Neurol Neurosurg Psychiatry 1992; 55: 181-84.
21. Dexter D, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38-44.
22. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997; 244: 262-65.
23. Maraganore D, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991; 6: 205-11.
24. Armstrong M, Idle J, Daly A. A polymorphic cfo I site in exon 6 of the human cytochrome P450IID6 gene detected by the polymerase chain reaction. Hum Genet 1993; 91: 616-17.
25. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′ flanking region. J Biochem 1994; 116: 321-26.
26. Rosvold E, McGlynn K, Lustbader E, Buetow K. Identification of an NAD(P)H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995; 5: 199-206.
27. Chen C-L, Liu Q, Relling M. Simultaneous characterisation of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996; 6: 187-91.
28. Bell D, Taylor J, Butler M, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-92.
29. Payami H, Joe S, Farid NR, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989:, 45: 541-46.
30. Snyder S, D'Amato R. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 1986; 36: 250-58,
31. Ladero J, Jimenez F, Benitez J, et al. Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 1989; 37: 391-93.
32. Igbokwe E, Ogunniyi A, Osuntokun B. Xenobiotic metabolism in idiopathic Parkinson's disease in Nigerian Africans. East Afr Med J 1993; 70: 807-09.
33. Peters L, Steventon G, Green S, Sturman S, Waring R, Williams A. D-penicillamine metabolism in neurodegenerative disease: an in vivo/in vitro sulphydryl methylation study. Xenobiotica 1994; 24: 1013-20
34. Risch A, Wallace D, Bathers S, Sim E. Slow N-acetylation genotype is a subsequent factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4: 231-36.
35. Blum M, Demierre A, Grant D, Heim M, Meyer U. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci 1991; 88: 5237-41.
36. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature 1994; 369: 154-56.